|
|
|
27.03.25 - 09:36
|
Headline: InflaRx bleibt eine Geduldsprobe für Anleger (GoingPublic)
|
|
|
Bildnachweis: InflaRx, stock3.com, Kristina Blokhin – stock.adobe.com. Die seit Ende 2017 an der Nasdaq gelistete Biotechfirma aus Jena bleibt bei den Einnahmen aus ihrem ersten zugelassenen Medikament bislang deutlich unter […]
Der Beitrag Headline: InflaRx bleibt eine Geduldsprobe für Anleger erschien zuerst auf GoingPublic.de....
|
|
|
|
|
|
|
|
|
07.03.25 - 14:03
|
InflaRx Showcases Vilobelimab′s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting (GlobeNewswire EN)
|
|
|
JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses. These data are being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting being held March 7 - 11, in Orlando, FL....
|
|
|
28.02.25 - 15:03
|
InflaRx to Showcase Vilobelimab′s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting (GlobeNewswire EN)
|
|
|
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL....
|
|
|
|
|
|
|
18.02.25 - 22:03
|
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares. The purchase price of each pre-funded warrant was equal to the price per share at which ordinary shares were sold to the public in this offering, minus $0.001, which is the exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering were approximately $30 million, before deducting the underwriting discount and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to 2,250,000 additional ordinary shares at the public offering pr...
|
|
|
|
|
14.02.25 - 03:48
|
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten public offering of 8,250,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares. The purchase price of each pre-funded warrant is equal to the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which is the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are being sold by the Company. The offering is expected to close on February 18, 2025, subject to the satisfaction of customary closing conditions....
|
|
|
|
|
13.02.25 - 22:03
|
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company's ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are to be sold by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering....
|
|
|
|
|
17.01.25 - 11:48
|
InflaRx: Spannende Phase (Boersengefluester)
|
|
|
Vor wenigen Jahren wäre der Aktienkurs von InflaRx bei so einer Meldung vermutlich durch die Decke gegangen. Immerhin hat das Biotechunternehmen aus Jena mit Listing an der Nasdaq die EU-weite Zula......
|
|
|
|
|
16.01.25 - 11:24
|
InflaRx Aktie: Wichtiger Meilenstein (Aktiencheck)
|
|
|
Kulmbach (www.aktiencheck.de) - InflaRx-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie der Biotech-Schmiede InflaRx N.V. (ISIN: NL0012661870, WKN: A2H7A5, Ticker-Symbol: IF0, NASDAQ-Symbol: IFRX) unter die Lupe.
Die deutsche Biotech-Gesellschaft InflaRx könne einen wichtigen Meilenstein verbuchen. [mehr]...
|
|
|
16.01.25 - 10:57
|
InflaRx: Zulassung! (Der Aktionaer)
|
|
|
Die deutsche Biotech-Gesellschaft InflaRx kann einen wichtigen Meilenstein verbuchen. Denn die Europäische Kommission hat die Zulassung für Gohibic (Vilobelimab) zur Behandlung des SARS-CoV-2-induzierten akuten Atemnotsyndrom (ARDS) zugelassen. Es ist die erste Therapie zugelassene Therapie in dieser Indikation überhaupt....
|
|
|
|
|
16.01.25 - 08:24
|
InflaRx erhält Marktzulassung der Europäischen Kommission für GOHIBIC (GoingPublic)
|
|
|
Diese Nachricht basiert auf einer Pressemitteilung von www.inflarx.com. InflaRx N.V. (WKN: A2H7A5, ISIN: NL0012661870, Nasdaq: IFRX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Anti-Inflammationstherapien spezialisiert hat, gibt bekannt, dass […]
Der Beitrag InflaRx erhält Marktzulassung der Europäischen Kommission für GOHIBIC erschien zuerst auf GoingPublic.de....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
